Chronic obstructive pulmonary disease and cardiovascular risk;EPOC y riesgo cardiovascular

Archivos de Bronconeumologia

Volumn 41, Issue 8, 2005, Pages 410-412

  Izquierdo Alonso, J L ^a   Arroyo Espliguero, R ^a  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; EDITORIAL; PNEUMONIA; SPAIN;

EID: 25144502310     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13077950     Document Type: Editorial

References (34)

1. Barberà JA, Peces-Barba G, Agustí AGN, et al. Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2001;37:297-316.
2. Jaén Díaz JI, Castro Mesa C, Gontán García-Salamanca MJ, López de Castro F. Prevalencia y factores de riesgo de EPOC en fumadores y ex fumadores. Arch Bronconeumol. 2003;39:554-8.
3. Conferencia de Consenso sobre EPOC. Arch Bronconeumol. 2003;39 Supl 3:1-47.
4. Izquierdo JL. The burden of COPD in Spain: results from the confronting survey. Respir Med. 2003;97:S61-S9.
5. Escarrabill J. Costes sanitarios de la enfermedad pulmonar obstructiva crónica (EPOC). Arch Bronconeumol. 2003;39:435-6.
6. Izquierdo JL, De Miguel J. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. Journal of COPD. 2004;1:215-23.
7. Izquierdo Alonso JL, Jiménez de Castro D. Presente y futuro en el tratamiento de la EPOC. Arch Bronconeumol. 2001;37:34-81.
8. Izquierdo Alonso JL. EPOC y asma. Arch Bronconeumol. 2001; 37:1-2.
9. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001;163:1256-76.
10. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J. 2003;22:809-14.
11. The TORCH study group. The TORCH (Towards a Revolution in COPD Health) survival study protocol. Eur Respir J. 2004;24:206-10.
12. Soriano JB, Vestbo J, Pride NB. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 2003;21:559-60.
13. Kim WD, Eidelman D, Izquierdo JL, et al. Centrilobular and panlobular emphysema in smokers. Two distinct morphological and functional entities. Am Rev Respir Dis. 1991;144:1385-90.
14. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-80.
15. Wouters EFM, Creutzberg EC, Schools AM. Systemic effects in COPD. Chest. 2002;121:127S-30S.
16. Schunemann HJ, Dorn J, Grant BJ, et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118: 656-64.
17. Bang KM, Gergen PJ, Kramer R, et al. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest. 1993;103:536-40.
18. Hole DJ, Watt GC, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313:711-5.
19. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-26.
20. Engstrom G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation. 2002;106:2555-60.
21. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9.
22. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
23. Koenig W, Lowel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109:1349-53.
24. Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, et al. C-reactive protein elevation and disease activity in patients with coronary heart disease. Eur Heart J. 2004;25:401-8.
25. Arroyo-Espliguero R, Avanzas P, Kaski JC. Enfermedad cardiovascular ateroesclerótica: la utilidad de la proteína C reactiva en la identificación de la placa vulnerable y del paciente vulnerable. Rev Esp Cardiol. 2004;57:375-8.
26. Zouridakis E, Avanzas P, Arroyo-Espliguero R, et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation. 2004;110:1747-53.
27. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-43.
28. Verma S, Li S, Badiwala M, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:1890-6.
29. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514-9.
30. Dahl M, Tybjaerg-Hansen A, Vestbo J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Crit Care Med. 2001;164:1008-11.
31. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:760-5.
32. Arroyo-Espliguero R, Avanzas P, Jeffery S, et al. CD 14 and toll-like receptor 4: a link between infection and acute coronary events? Heart. 2004;90:983-8.
33. Roland M, Bhowmik A, Sapsford RJ, et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax. 2001;56:30-5.
34. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000;84:210-5.